Chrysalis Biotherapeutics
Saving Lives
Through Innovation
Chrysalis is pioneering the use of natural regenerative peptides to restore vascular function and activate normal stem cell populations where they exist in the body to accelerate tissue repair and prevent damaging effects of trauma, disease, ischemia, and radiation exposure
Solution for Radiation Induced Tissue Damage
Development of drugs to selectively reduce radiotherapy-induced normal tissue damage may improve post-therapy quality of life and save lives.
Solution for Nuclear Radiation Exposure
A single TP508 injection 24 hours after a lethal dose of whole body radiation significantly increases survival and reduces delayed effects of radiation.
TP508 Peptide Technology
The TP508 thrombin peptide is released locally following vascular injury to initiate cellular regenerative processes that lead to revascularization, stem cell activation, and tissue repair.
Covid-19
TP508, targets endothelial cells to restore vascular function and modulate immune responses
after injury. A single injection of TP508 24 hours after SARS-CoV-2 infection almost completely
blocks the CoV-2 virus-induced cytokine storm in animal models.
TP-508 Clinical Pipeline
| INDICATION | Pre-Clinical Studies | IND Enabling Studies/cGMP Manufacturing | Phase 1/2 | |||
|---|---|---|---|---|---|---|
| Moderate/Severe Covid-19 | | |||||
| Brain Cancer Radiation Therapy | | |||||
| Traumatic Brain Injury | | |||||
| Nuclear Countermeasure/Acute Exposure | | |||||
Latest Press Releases
Galveston firm gets $10 million to study radiation antidote
By MYER LEE The Daily News Dec 13, 2020 Darrell Carney’s company, Chrysalis BioTheraputics, received $10.4 million to continue developing TP508, a drug that remedies
Chrysalis BioTherapeutics Receives $10.4 Million From BARDA to Continue Development of TP508 as a Nuclear Countermeasure
December 01, 2020 09:10 AM Eastern Standard Time GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company focused on the development of regenerative medicines to
Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development
Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing
Chrysalis BioTherapeutics Receives Funding from the National Institutes of Health for COVID-19 Therapeutic Development
GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs for acute organ injury caused by radiation exposure, announced today that the National
